

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

Altus Pharmaceuticals Inc.  
Form SC 13G  
December 31, 2007

OMB APPROVAL  
OMB Number: 3235-0145  
Expires: February 28, 2009  
Estimated average burden  
hours per response 10.4

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. \_\_)\*

ALTUS PHARMACEUTICALS, INC.

-----  
(Name of Issuer)

COMMON STOCK

-----  
(Title of Class of Securities)

02216N105

-----  
(CUSIP Number)

DECEMBER 20, 2007

-----  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

1

-----  
CUSIP No. 02216N105  
-----

13G

-----  
Page 2 of 9 Pages  
-----

1. NAMES OF REPORTING PERSONS

Great Point Partners, LLC

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

37-1475292

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF SHARES

5. SOLE VOTING POWER

0

BENEFICIALLY

6. SHARED VOTING POWER

OWNED BY EACH

1,868,195

REPORTING PERSON

7. SOLE DISPOSITIVE POWER

0

WITH

8. SHARED DISPOSITIVE POWER

1,868,195

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,868,195

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
(See Instructions)

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.08%

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

12. TYPE OF REPORTING PERSON (See Instructions)

OO

-----  
CUSIP No. 02216N105  
-----

13G

-----  
Page 3 of 9 Pages  
-----

1. NAMES OF REPORTING PERSONS

Dr. Jeffrey R. Jay, M.D.

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF SHARES

5. SOLE VOTING POWER

0

BENEFICIALLY

6. SHARED VOTING POWER

OWNED BY EACH

1,868,195

REPORTING PERSON

7. SOLE DISPOSITIVE POWER

0

WITH

8. SHARED DISPOSITIVE POWER

1,868,195

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,868,195

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
(See Instructions)

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.08%

12. TYPE OF REPORTING PERSON (See Instructions)

IN

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

-----  
CUSIP No. 02216N105  
-----

13G

-----  
Page 4 of 9 Pages  
-----

1. NAMES OF REPORTING PERSONS

Mr. David Kroin

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF SHARES	5. SOLE VOTING POWER	0
BENEFICIALLY	6. SHARED VOTING POWER	
OWNED BY EACH		1,868,195
REPORTING PERSON	7. SOLE DISPOSITIVE POWER	0
WITH	8. SHARED DISPOSITIVE POWER	1,868,195
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
		1,868,195
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)		<input type="checkbox"/>
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
		6.08%
12. TYPE OF REPORTING PERSON (See Instructions)		
		IN

-----  
CUSIP No. 02216N105  
-----

13G

-----  
Page 5 of 9 Pages  
-----

ITEM 1.

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

- (a) Name of Issuer  
Altus Pharmaceuticals Inc.
- (b) Address of Issuer's Principal Executive Offices  
125 Sidney Street, Cambridge, MA 02139

ITEM 2.

- (a) Name of Person Filing  
Great Point Partners, LLC  
Dr. Jeffrey R. Jay, M.D.  
Mr. David Kroin

The Reporting Persons have entered into a Joint Filing Agreement, dated December 31, 2007, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

- (b) Address of Principal Business Office, or if none, Residence  
The address of the principal business office of each of the Reporting Persons is  
165 Mason Street, 3rd Floor  
Greenwich, CT 06830

- (c) Citizenship

Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.

- (d) Title of Class of Securities  
Common Stock

- (e) CUSIP Number  
02216N105

ITEM 3.

IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(B) OR 240.13D.2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

Not Applicable.

- (a)  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
- (b)  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)  Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

- (e)  An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E).

-----  
CUSIP No. 02216N105  
-----

13G

-----  
Page 6 of 9 Pages  
-----

- (f)  An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F).
- (g)  A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G).
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i)  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j)  Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP

Great Point Partners, LLC ("Great Point") is the investment manager of Biomedical Value Fund, L.P. ("BVF"), and by virtue of such status may be deemed to be the beneficial owner of the 1,008,828 shares of Common Stock of the Issuer owned by BVF (the "BVF Shares"). Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares.

Great Point is the investment manager of Biomedical Offshore Value Fund, Ltd. ("BOVF"), and by virtue of such status may be deemed to be the beneficial owner of the 859,367 shares of Common Stock of the Issuer owned by BOVF (the "BOVF Shares"). Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares.

Each of Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to the extent of their respective pecuniary interest.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

1. GREAT POINT PARTNERS, LLC
  - (a) Amount beneficially owned: 1,868,195
  - (b) Percent of class: 6.08%

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote: - 0 -
  - (ii) Shared power to vote or to direct the vote:  
1,868,195
  - (iii) Sole power to dispose or to direct the disposition  
of: - 0 -.
  - (iv) Shared power to dispose or to direct the  
disposition of: 1,868,195
2. DR. JEFFREY R. JAY, M.D.
- (a) Amount beneficially owned: 1,868,195
  - (b) Percent of class: 6.08%

-----  
CUSIP No. 02216N105  
-----

13G

-----  
Page 7 of 9 Pages  
-----

- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote: 0.
  - (ii) Shared power to vote or to direct the vote:  
1,868,195
  - (iii) Sole power to dispose or to direct the disposition  
of: 0.
  - (iv) Shared power to dispose or to direct the  
disposition of: 1,868,195
3. MR. DAVID KROIN
- (a) Amount beneficially owned: 1,868,195
  - (b) Percent of class: 6.08%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote: 0.
  - (ii) Shared power to vote or to direct the vote:  
1,868,195
  - (iii) Sole power to dispose or to direct the disposition  
of: 0.
  - (iv) Shared power to dispose or to direct the  
disposition of: 1,868,195

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

- ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS  
Not Applicable.
- ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:  
See Item 4.
- ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY  
Not Applicable.
- ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP  
Not Applicable.
- ITEM 9. NOTICE OF DISSOLUTION OF GROUP  
Not Applicable.
- ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

-----  
CUSIP No. 02216N105  
-----

13G

-----  
Page 8 of 9 Pages  
-----

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 31, 2007

GREAT POINT PARTNERS, LLC

By: /s/ DR. JEFFREY R. JAY, M.D.

-----  
Dr. Jeffrey R. Jay, M.D.,  
as senior managing member

/s/ DR. JEFFREY R. JAY, M.D.

-----  
DR. JEFFREY R. JAY, M.D.

/s/ MR. DAVID KROIN

-----  
MR. DAVID KROIN



EXHIBIT A

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree as follows:

(i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and

(ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: December 31, 2007

GREAT POINT PARTNERS, LLC

By: /s/ DR. JEFFREY R. JAY, M.D.

-----  
Dr. Jeffrey R. Jay, M.D.,  
as senior managing member

/s/ DR. JEFFREY R. JAY, M.D.

-----  
DR. JEFFREY R. JAY, M.D.

/s/ MR. DAVID KROIN

-----  
MR. DAVID KROIN